I am happy to announce the launch of our new campaign, Harmony in Hemophilia, aimed at enhancing relationships between our member HTCs, NHF Chapters and HFA Member Organizations.
As of this writing, the Congressional August recess is waning and all eyes turn to the September calendar, which holds several challenges for policymakers.
Under the auspices of 340B Program compliance, manufacturers recently requested extensive data from covered entities related to drugs dispensed through contract pharmacies.
Wow, after waiting 25 plus years for a gene therapy product for the hemophilia community, it never occurred to me that Biomarin’s product would be rejected by the FDA last week with a call for additional data on the durability of their product.
